IRIS
DI MARIO, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.796
AS - Asia 31.742
EU - Europa 16.847
SA - Sud America 4.125
AF - Africa 1.584
Continente sconosciuto - Info sul continente non disponibili 65
OC - Oceania 63
Totale 87.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.881
SG - Singapore 11.903
CN - Cina 8.940
VN - Vietnam 4.337
IE - Irlanda 3.643
SE - Svezia 3.304
BR - Brasile 3.212
IT - Italia 2.080
HK - Hong Kong 2.066
TR - Turchia 1.525
DE - Germania 1.421
UA - Ucraina 1.259
FI - Finlandia 1.208
ZA - Sudafrica 1.087
BD - Bangladesh 1.020
NL - Olanda 974
FR - Francia 965
RU - Federazione Russa 563
GB - Regno Unito 557
CA - Canada 550
IN - India 391
AR - Argentina 332
IQ - Iraq 196
MX - Messico 188
CI - Costa d'Avorio 178
JP - Giappone 165
BE - Belgio 154
EC - Ecuador 149
ID - Indonesia 148
PL - Polonia 120
PH - Filippine 117
CO - Colombia 115
AT - Austria 109
PK - Pakistan 109
KR - Corea 99
TH - Thailandia 91
ES - Italia 86
UZ - Uzbekistan 86
VE - Venezuela 80
MA - Marocco 71
PY - Paraguay 67
CL - Cile 65
SA - Arabia Saudita 62
LT - Lituania 61
AU - Australia 59
EU - Europa 59
EG - Egitto 57
TW - Taiwan 55
RO - Romania 52
IR - Iran 49
KE - Kenya 48
AE - Emirati Arabi Uniti 45
CZ - Repubblica Ceca 44
TN - Tunisia 44
MY - Malesia 42
PE - Perù 38
IL - Israele 37
AZ - Azerbaigian 35
JO - Giordania 34
HU - Ungheria 32
UY - Uruguay 31
CR - Costa Rica 30
DZ - Algeria 30
BO - Bolivia 29
BG - Bulgaria 28
JM - Giamaica 26
PA - Panama 26
DO - Repubblica Dominicana 23
PT - Portogallo 22
CH - Svizzera 20
NP - Nepal 20
AL - Albania 19
KG - Kirghizistan 19
LB - Libano 18
SK - Slovacchia (Repubblica Slovacca) 17
HN - Honduras 16
OM - Oman 16
KZ - Kazakistan 15
RS - Serbia 14
HR - Croazia 12
SN - Senegal 12
BH - Bahrain 11
BY - Bielorussia 11
GR - Grecia 11
PS - Palestinian Territory 11
TT - Trinidad e Tobago 11
ET - Etiopia 10
LV - Lettonia 10
MD - Moldavia 10
GE - Georgia 9
GT - Guatemala 9
SY - Repubblica araba siriana 9
DK - Danimarca 8
LK - Sri Lanka 8
LY - Libia 8
SV - El Salvador 8
AM - Armenia 7
EE - Estonia 7
KH - Cambogia 7
KW - Kuwait 7
Totale 87.079
Salva come PNG Salva come JPEG
Città #
Singapore 5.560
Chandler 4.808
Ashburn 3.720
Dublin 3.632
San Jose 2.729
Santa Clara 2.245
Hong Kong 1.958
Beijing 1.817
Dearborn 1.619
Ho Chi Minh City 1.405
Nanjing 1.317
Izmir 1.236
Jacksonville 1.223
Boardman 1.190
Dallas 1.038
Johannesburg 1.027
Hanoi 973
Princeton 831
New York 803
Lauterbourg 721
Los Angeles 569
Shanghai 520
Wilmington 464
San Mateo 447
Munich 435
Moscow 433
Helsinki 426
Ann Arbor 399
Shenyang 379
Nanchang 360
Columbus 330
Toronto 307
Hebei 297
São Paulo 285
Tianjin 251
Kunming 243
Buffalo 228
Changsha 227
Jinan 227
Hefei 220
Jiaxing 203
Da Nang 180
Parma 176
Haiphong 174
Kocaeli 174
Abidjan 171
Frankfurt am Main 158
Genoa 149
Guangzhou 149
Chicago 148
Brussels 136
The Dalles 133
Norwalk 131
Seattle 130
Tokyo 124
Hangzhou 121
Milan 115
Tito 114
Turku 106
Council Bluffs 104
Zhengzhou 104
London 100
Rome 98
Fremont 93
Pune 93
Brooklyn 90
Orem 88
Rio de Janeiro 88
Warsaw 87
Montreal 86
Atlanta 80
Houston 78
Baghdad 77
Des Moines 77
Vienna 76
Denver 73
Nardò 73
Bremen 70
Stockholm 70
Belo Horizonte 69
Hải Dương 69
Ningbo 69
Tashkent 69
Phoenix 67
Biên Hòa 66
Nuremberg 66
San Francisco 62
Chennai 61
Taranto 61
Porto Alegre 57
Boston 56
Can Tho 56
Naples 52
Woodbridge 52
Curitiba 49
Quito 49
Washington 49
Bologna 48
Brasília 47
Dhaka 46
Totale 52.616
Salva come PNG Salva come JPEG
Nome #
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 487
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 420
CS1.1 EFFICACY OF MESALAMINE AND THE ASSOCIATION OF MESALAMINE AND PROBIOTICS VERSUS RIFAXIMIN IN THE TREATMENT OF SYMPTOMATIC DIVERTICULAR DISEASE 293
Coffee intake and gastroesophageal reflux: Relationship with clinical, endoscopic and functional features 242
Studio della lattoferrina nel succo pancreatico-duodenale. Limiti nelle diagnosi di pancreatite cronica 214
Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine 212
Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD 208
Burning Mouth Syndrome Etiology: A Narrative Review 194
Recovery of gastric function in patients affected by chronic atrophic gastritis using L-cysteine (Acetium®): one year survey in comparison with a control group 188
Thyroid and celiac disease in pediatric age: a literature review 187
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 185
Approach to gastroenterological diseases in primary care 185
How and when investigating and treating Helicobacter pylori infection in children 183
Eosinophilic esophagitis in pediatric age, state of the art and review of the literature 177
Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy 174
Long-term treatment for gastric and duodenal ulcer 173
Is it possible to withdrawal PPI’s therapy in GERD patients? A prospective study on 216 patients using HYCHSA 171
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 169
Microsatellite instability in colorectal cancer 168
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety 167
Individualized treatment of duodenal ulcer disease. A pilot study 166
Endoscopic ultrasound in pediatric population: a comprehensive review of the literature 165
Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact? 164
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 164
Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against “SARS-CoV-2 Nephropathy 163
Barrett’s esophagus: results from an Italian cohort with tight endoscopic surveillance 163
Advanced gastric cancer: the value of surgery 162
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. 161
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 161
H2-blockers in the treatment of ulcer disease in the elderly 161
Helicobacter pylori infection in asymptomatic elderly subjects living at home or in a nursing home: effects on gastric function and nutritional status 160
[Morpho-functional characteristics of reflux gastritis in patients after cholecystectomy and without cholecystectomy] 160
[Cisapride and sucralfate in dyspepsia associated with duodenogastric reflux gastritis] 160
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 159
Biochemical and histopathological aspects in duodenogastric reflux gastritis patients with or without prior cholecystectomy 159
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 158
[Clinical usefulness of the blood gastrin curve after protein meal in duodenal ulcer] 158
Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases 158
A non-invasive method for the diagnosis of upper GI diseases 158
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers 158
Comparison of three different therapeutic regimens for eradicating Helicobacter pylori 158
CONNECTIONS BETWEEN GENETICS ANCùD CLINICAL DATA:ROLE OF MCP-1 , CFTR AND SPINK-1 IN THE CLINICAL SETTING OF ACUTE,ACUTE RECURRENT AND CHRONIC PANCREATITIS. 156
Gastric function assessed by Gastropanel in very old patients (over 80 years old) and appropriateness of PPIs administration 156
Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study 156
Current concepts in the management of helicobacter pylori infection: The maastricht III consensus report 156
Conservative treatment of acute appendicitis 156
Burning mouth syndrome and Reflux Disease: relationship and clinical implications 156
A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy 155
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 155
Epidemiology and risk factors of pancreatic cancer 155
Growth changes after gluteen free diet in pediatric celiac patients: a literature-review 154
Association of keratin 8 gene mutation with chronic pancreatitis 153
Acid-related disorders in the elderly 153
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 153
Different effects of H. pylori water extracts on cytokines, pepsinogen C and gastrin mucosal release in patients with or without duodenal ulcer 153
Clinical markers of slow healing and relapsing gastric ulcer 153
[Clinical usefulness of endoscopy of the upper digestive tract in the aged] 153
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. 152
Does chronic hypercalcemia influence serum pepsinogens levels? 152
Gastro panel® for detection of atrophic gastritis: The “Parma model” 152
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 152
Cimetidine, ranitidine, and pirenzepine in the treatment of duodenal ulcer: A six-month low-dose treatment period followed by a six-month observation period 151
10 Day bismuth-based quadruple therapy for HP eradication in comparison with other therapies in a population with high clarithromycin resistance in northeast Italy 151
Epidemiology and risk factors for diverticular disease 151
THE SLEEPING REMNANT 150
Risk of tumor implantation in percutaneous endoscopic gastrostomy in the upper aerodigestive tumors 150
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 150
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. 149
RANITIDINA E NIZATIDINA NELL'ULCERA PEPTICA DELL'ANZIANO: STUDIO MULTICENTRICO, IN DOPPIO CIECO, A BREVE TERMINE 149
Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.--Interdisciplinary Group on Gastric Epithelial Dysplasia 149
Serum pepsinogen II for early assessment of success of H. pylori eradication 148
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 147
Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study 147
800 mg of cimetidine versus 300 mg of ranitidine at bedtime in the short-term treatment of duodenal ulcer: A cost/benefit study 147
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 147
Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard 147
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 147
[Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer] 147
Treatment of Helicobacter pylori infection. 146
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 146
M1695 Serum Pepsinogens and Topography of Chronic Atrophic Gastritis in a Population Sample Referred for Endoscopy 146
Efficacy of 5-ASA in the treatment of colonic diverticular disease 146
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 145
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status 145
Helicobacter pylori, transmission routes and recurrence of infection: state of the art 145
ASSESSMENT OF SYMPTOMS IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD) 145
Is the risk of contrast-induced nephropathy a real contraindication to perform intravenous contrast enhanced Computed Tomography for non-traumatic acute abdomen in Emergency Surgery Department? 145
ACID SUPPRESSION THERAPY: WHERE DO WE FROM HERE? 144
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 144
TERAPIA DI MANTENIMENTO PER UN ANNO CON ANTI-H2 NELL'ULCERA PEPTICA DELL'ANZIANO: IMPORTANZA DELLA SINTOMATOLOGIA COME MARKER DI RECIDIVA 144
Cancer adenomas founbd during 15 years of screening in the Alto Vicentino area (north-east Italy) 144
[Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study] 143
[Alcohol-dependent mast cell activation in ulcer] 143
Gastric and duodenal ulcer in the same patient 143
A symptom-orientated PPI strategy in the treatment of the ENT manifestations of GERD. 142
ASPETTI METODOLOGICI DEL SONDAGGIO GASTRICO 142
M1261 Recurrence of Diverticulitis in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) Treated Cyclically With Mesalamine: Result of a Follow-up Study 142
P.02.8: Chronic Atrophic Gastritis is Related with an Increased Risk for Cardiovascular Diseases, Assessed by Homocysteine Serum Levels Determination 141
T1979 Pepsinogen II As Marker of Inflammation in H.P Infection and in NSAIDs Damage 141
A comparison of five maintenance therapies for reflux esophagitis 141
Totale 16.544
Salva come PNG Salva come JPEG
Categoria #
all - tutte 314.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 314.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 0 0 0 0 0 0 54
2021/20223.602 47 23 52 224 206 59 213 444 176 310 342 1.506
2022/202314.711 1.540 1.337 984 1.304 1.153 1.798 103 1.127 4.622 60 555 128
2023/20244.820 251 577 136 136 414 1.364 214 351 145 282 398 552
2024/202516.639 347 988 1.140 853 1.997 1.879 504 660 2.511 1.562 1.396 2.802
2025/202633.067 3.017 3.075 3.337 2.646 4.984 2.242 3.491 962 4.228 2.490 1.519 1.076
Totale 87.957